




RealRate

PHARMACEUTICAL 2017

Intercept Pharmaceuticals INC
Rank 212 of 308



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Intercept Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Intercept Pharmaceuticals INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 46% points. The greatest weakness of Intercept Pharmaceuticals INC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 127% points.

The company's Economic Capital Ratio, given in the ranking table, is 186%, being 59% points below the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	707,865
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	78,512
Liabilities, Non-Current	341,356
Other Assets	20,093
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	4,453
Other Net Income	-10,292
Other Revenues	24,951
Property and Equipment	11,295
Research and Development	153,893
Selling, General and Administrative Expense	273,596

Output Variable	Value in 1000 USD
Assets	739,253
Liabilities	424,321
Expenses	427,489
Revenues	24,951
Stockholders Equity	314,932
Net Income	-412,830
Comprehensive Net Income	-412,830
BaseVar	813,153
ECR before LimitedLiability	47%
Economic Capital Ratio	186%